公开(公告)号：US20240358765A1

公开(公告)日：2024-10-31

申请号：US18767576

申请日：2024-07-09

Applicant: Terumo Kabushiki Kaisha ,  Osaka University

Inventor： Hidetoshi EGUCHI ,  Yoshito TOMIMARU ,  Shigeru MIYAGAWA ,  Keisuke TOYA ,  Fumiya OHASHI

IPC: A61K35/34 ,  A61P1/16 ,  C12N5/077

CPC classification number: A61K35/34 ,  A61P1/16 ,  C12N5/0658 ,  C12N2502/28

Abstract: A composition comprising skeletal myoblasts for treating liver dysfunction or improving liver function, in which the liver dysfunction can be hepatitis, liver fibrosis, liver cirrhosis, liver cancer, or liver failure. The composition can be used for promoting the proliferation of liver cells, regeneration of the liver tissue and/or angiogenesis, and providing a method for treating liver dysfunction, including a step of treating applying the composition to a site exhibiting liver dysfunction.

公开(公告)号：US20240350595A1

公开(公告)日：2024-10-24

申请号：US18392854

申请日：2023-12-21

Applicant: The Trustees of the University of Pennsylvania

Inventor： Daniel Rader ,  Devin Christopher ,  Anna P. Tretiakova

IPC: A61K38/45 ,  A61K38/00 ,  A61K48/00 ,  A61P1/16 ,  A61P9/00 ,  C12N9/10 ,  C12N15/86 ,  C12P21/02

CPC classification number: A61K38/45 ,  A61K48/0058 ,  A61P1/16 ,  A61P9/00 ,  C12N9/1029 ,  C12N15/86 ,  C12P21/02 ,  A61K38/00 ,  C12N2750/14143 ,  C12Y203/01043

Abstract: A synthetic or recombinant human lecithin cholesterol acyltransferase (LCAT) variant is provided which comprises an LCAT enzyme having a substitution at position 114 based on the residue numbering of wild-type (WT) human LCAT [SEQ ID NO:1], wherein said variant is characterized by one or more of: (i) an esterification rate higher than the esterification rate of WT human LCAT; and/or (ii) an association with higher density lipoprotein levels as compared to subjects having WT LCAT. Also provided are vectors encoding the variant, compositions containing same, and methods of using the variant proteins and vectors for treatment of a variety of disorders associated with defective wt LCAT.

公开(公告)号：US20240342212A1

公开(公告)日：2024-10-17

申请号：US18753638

申请日：2024-06-25

Applicant: Alkahest, Inc.

Inventor： Viktoria Kheifets ,  Benson Lu

IPC: A61K35/16 ,  A61P1/16

CPC classification number: A61K35/16 ,  A61P1/16

Abstract: Methods and compositions for treating aging-related diseases as well as liver regeneration, prevention of liver degeneration, and maintenance of liver are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing disease.

公开(公告)号：US12116362B2

公开(公告)日：2024-10-15

申请号：US17959064

申请日：2022-10-03

Applicant: Valo Health, Inc.

Inventor： Brian Raimundo ,  Elena S. Koltun ,  John Griffin ,  Eric Stangeland

IPC: C07D417/14 ,  A61P1/16 ,  A61P3/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  C07D401/04 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04

CPC classification number: C07D417/14 ,  A61P1/16 ,  A61P3/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  C07D401/04 ,  C07D401/14 ,  C07D417/04 ,  C07D471/04

Abstract: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.

公开(公告)号：US12109190B2

公开(公告)日：2024-10-08

申请号：US17822027

申请日：2022-08-24

Applicant: Amazentis SA

Inventor： Anurag Singh ,  Davide D'Amico ,  Penelope Andreux ,  William Blanco-Bose ,  Christopher L. Rinsch

IPC: A61K31/37 ,  A61K31/335 ,  A61K39/00 ,  A61K39/145 ,  A61K39/39 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P31/16 ,  A61P35/00 ,  C07D311/80

CPC classification number: A61K31/37 ,  A61K31/335 ,  A61K39/0011 ,  A61K39/145 ,  A61K39/39 ,  A61P31/16 ,  A61K2039/55 ,  A61K2039/55511 ,  A61P1/04 ,  A61P1/16 ,  A61P1/18 ,  A61P13/12 ,  A61P17/00 ,  A61P19/02 ,  A61P19/08 ,  A61P21/00 ,  A61P35/00 ,  C07D311/80 ,  A61K2300/00 ,  A61K31/366

Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.

公开(公告)号：US20240325497A1

公开(公告)日：2024-10-03

申请号：US18580971

申请日：2022-08-03

Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY

Inventor： Cheol Ryong KU ,  Ju Hun OH ,  Chan Woo KANG ,  Eun Kyung WANG ,  Zhenyu HONG ,  Yong Ho LEE

IPC: A61K38/22 ,  A61K9/00 ,  A61P1/16

CPC classification number: A61K38/22 ,  A61K9/0056 ,  A61P1/16

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver disease comprising STC-1 or a derivative thereof as an active ingredient. The STC-1 protein according to the present invention reduces the expression of liver fibrosis markers ALT and Lect2 and reduces the area of fibrotic tissue, in animal models of liver fibrosis, indicating that it has excellent effects on the prevention and treatment of liver fibrosis and, furthermore, cirrhosis.

公开(公告)号：US20240307502A1

公开(公告)日：2024-09-19

申请号：US18673424

申请日：2024-05-24

Applicant: Gilead Sciences, Inc. ,  Novo Nordisk A/S

Inventor： Constantine Stephen Djedjos ,  Bryan John McColgan ,  Robert Paul Myers ,  Gangadharan Mani Subramanian ,  Lene Melchiorsen ,  Morten Hansen

IPC: A61K38/26 ,  A61K9/00 ,  A61K31/4439 ,  A61K31/519 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

CPC classification number: A61K38/26 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/4439 ,  A61K31/519 ,  A61P1/16 ,  A61P3/04 ,  A61P3/10

Abstract: The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.

公开(公告)号：US12091664B2

公开(公告)日：2024-09-17

申请号：US16961062

申请日：2019-01-11

Applicant: UNIVERSITY OF MASSACHUSETTS

Inventor： Paulo Martins ,  Xiaofei E. ,  Timothy Kowalik

IPC: C12N15/113 ,  A61P1/16 ,  A61P9/10

CPC classification number: C12N15/1135 ,  A61P1/16 ,  A61P9/10 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/30

Abstract: The invention provides methods for treating ischemia (such as ischemia repertusion injury (IRI)) in tissue (such as transplant donor tissue), comprising contacting the tissue during ex vivo perfusion with a therapeutically effective amount of RNAi (such as siRNA) that specifically hinds to at least a portion of a gene (such as p53) that mediates ischemic injury in the tissue. The invention's methods additionally decrease the risk of tissue rejection and/or or induce immunological tolerance to transplanted tissue.

公开(公告)号：US12090141B2

公开(公告)日：2024-09-17

申请号：US16869312

申请日：2020-05-07

Applicant: Eiger Group International, Inc.

Inventor： Jeffrey S. Glenn ,  Edward A. Pham

IPC: A61K45/06 ,  A61K31/4184 ,  A61K31/4706 ,  A61P1/16 ,  A61P29/00 ,  A61P35/00 ,  C07D215/46 ,  C07D235/14

CPC classification number: A61K31/4184 ,  A61K31/4706 ,  A61K45/06 ,  A61P1/16 ,  A61P29/00 ,  A61P35/00 ,  C07D215/46 ,  C07D235/14 ,  A61K31/4184 ,  A61K2300/00 ,  A61K31/4706 ,  A61K2300/00

Abstract: Disclosed herein are methods for use of clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory conditions. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.

公开(公告)号：US12090138B2

公开(公告)日：2024-09-17

申请号：US17588033

申请日：2022-01-28

Applicant: TASLY PHARMACEUTICAL GROUP CO., LTD.

Inventor： He Sun ,  Xijun Yan ,  Naifeng Wu ,  Kaijing Yan ,  Yonghong Zhu ,  Shunnan Zhang ,  Xiaolin Bai ,  Xiaohui Ma ,  Yi He ,  Ting Li ,  Lei Li

IPC: A61K31/357 ,  A61K9/08 ,  A61K9/16 ,  A61K9/48 ,  A61K31/205 ,  A61K31/355 ,  A61K31/683 ,  A61K36/488 ,  A61K36/82 ,  A61K47/24 ,  A61P1/16

CPC classification number: A61K31/357 ,  A61K9/08 ,  A61K9/1617 ,  A61K9/1682 ,  A61K9/48 ,  A61K31/205 ,  A61K31/355 ,  A61K31/683 ,  A61K36/488 ,  A61K36/82 ,  A61K47/24 ,  A61P1/16 ,  A61K2236/19

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.